Drugs / FG-M108
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07704866 | Jul 2026 → Aug 2028 expected | — | FutureGen Biopharmaceutical (Beijing) Co., Ltd | Not yet recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07383922 | Feb 2026 → Jun 2030 expected | malignant pancreatic neoplasm | FutureGen Biopharmaceutical (Beijing) Co., Ltd | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FG-M108 | “This open-label, multicenter Phase I/II trial evaluates the combination of FG-M108 and FG-B901 in patients with unresectable locally advanced or metastatic solid tumors” NCT07704866 ↗ |
| Modality | Monoclonal antibody | “FG-M108 monoclonal antibody will be administered as a minimum 2-hour Intravenous drip.” NCT07383922 ↗ |
| Route | Intravenous | “FG-M108 monoclonal antibody will be administered as a minimum 2-hour Intravenous drip.” NCT07383922 ↗ |